Claims for Patent: 10,570,103

Summary for Patent: 10,570,103

Title:	Heterocyclic compounds useful in the treatment of disease
Abstract:	A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.
Inventor(s):	Beaton; Graham (San Diego, CA), Tucci; Fabio C. (San Diego, CA), Ravula; Satheesh B. (San Diego, CA), Shah; Chandravadan R. (San Diego, CA), Luu; Hiep (San Marcos, CA)
Assignee:	EPIGEN BIOSCIENCES, INC. (San Diego, CA)
Application Number:	16/000,283
Patent Claims:	1. A method for treatment of a lysophosphatidic acid-dependent disease or condition in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound having the structure of Formula I ##STR00107## or a pharmaceutically acceptable salt or prodrug thereof, wherein R.sup.A is --CO.sub.2H, --CO.sub.2R.sup.B, --CN, tetrazolyl, --C(.dbd.O)NH.sub.2, --C(.dbd.O)NHR.sup.B, --C(.dbd.O)NHSO.sub.2R.sup.B, or --C(.dbd.O)NHCH.sub.2CH.sub.2SO.sub.3H or a carboxylic acid isostere selected from the group consisting of ##STR00108## wherein R.sup.B is --H or --C.sub.1-C.sub.4 alkyl or has the structure of one of: ##STR00109## L.sup.1 is absent or substituted or unsubstituted C.sub.1-C.sub.6 alkylene, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkylene, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkylene, or substituted or unsubstituted C.sub.1-C.sub.6 heteroalkylene; L.sup.2 is absent; Ring B has the structure of: ##STR00110## and is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where when Ring B is substituted then Ring B is substituted with 1, 2, or 3 independently selected R.sup.H, wherein A.sup.1, A.sup.2, and A.sup.3 are independently N or C; Ring A is a 5 membered heteroarene selected from one of: ##STR00111## wherein the dashed line indicates the point of attachment of Ring A to Ring B, wherein R.sup.C is --CN, --F, --Cl, --Br, --I, --OC.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 fluoroalkyl; and R.sup.D is --N(R.sup.F)--C(.dbd.O)XCH(R.sup.G)--CY, --N(R.sup.F)C(.dbd.O)XC(R.sup.G).sub.2--CY, --N(R.sup.F)C(.dbd.O)X--CY, --C(.dbd.O)N(R.sup.F)CH(R.sup.G)X--CY, or --C(.dbd.O)--N(R.sup.F)C(R.sup.G).sub.2X--CY, wherein X is absent, --O--, --NH-- or --CH.sub.2--; R.sup.E is --H, --C.sub.1-C.sub.4 alkyl or --C.sub.1-C.sub.4 fluoroalkyl; R.sup.F is --H or C.sub.1-C.sub.4 alkyl; R.sup.G is independently selected from R.sup.E, or one R.sup.G is C.sub.1-C.sub.4 alkyl and is taken together with CY and the carbon atom to which R.sup.G and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other R.sup.G, when present, is as defined for R.sup.E; CY is substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein when CY is substituted then CY is substituted with 1, 2, or 3 independently selected R.sup.H; wherein each R.sup.H is independently selected from --H, halogen, --CN, --NO.sub.2, --OH, --OR.sup.J, --SR.sup.J, --S(.dbd.O)R.sup.J, --S(.dbd.O).sub.2R.sup.J, --N(R.sup.J)S(.dbd.O).sub.2R.sup.J, --S(.dbd.O).sub.2N(R.sup.L).sub.2, --C(.dbd.O)R.sup.J, OC(.dbd.O)R.sup.J, --C(.dbd.O)OR.sup.J, --OC(.dbd.O)OR.sup.J, --N(R.sup.L).sub.2, --C(.dbd.O)N(R.sup.L).sub.2, --OC(.dbd.O)N(R.sup.L).sub.2, --N(R.sup.J)C(.dbd.O)N(R.sup.L).sub.2, --N(R.sup.J)C(.dbd.O)R.sup.J, --N(R.sup.J)C(.dbd.O)OR.sup.J, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 fluoroalkyl, C.sub.1-C.sub.4 fluoroalkoxy, C.sub.1-C.sub.4 alkoxy, and C.sub.1-C.sub.4 heteroalkyl, wherein each R.sup.J is independently substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6 heteroalkyl, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkyl, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heterocycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted aryl), or --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heteroaryl); wherein each R.sup.L is independently --H, substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6 heteroalkyl, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkyl, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted cycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heterocycloalkyl), --C.sub.1-C.sub.4 alkylene(substituted or unsubstituted aryl), or --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heteroaryl), or when R.sup.H is --S(.dbd.O).sub.2N(R.sup.L).sub.2, --N(R.sup.L).sub.2, --C(.dbd.O)N(R.sup.L).sub.2, --OC(.dbd.O)N(R.sup.L).sub.2 or N(R.sup.J)C(.dbd.O)N(R.sup.L).sub.2, each R.sup.L is independently --H or C.sub.1-C.sub.6 alkyl, or the R.sup.L groups independently are C.sub.1-C.sub.6 alkyl, which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle; and Ring C is substituted or unsubstituted C.sub.3-C.sub.10 cycloalkylene, substituted or unsubstituted C.sub.2-C.sub.10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where when Ring C is substituted then Ring C is substituted with 1, 2, or 3 independently selected R.sup.H, wherein R.sup.H is as previously defined. 2. The method according to claim 1, wherein the compound is selected from: 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-- 1-yl]phenyl]phenyl]acetic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-- pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-2-methyl-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y- l]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-py- razol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]pheny- l]acetic acid, 1-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]pheny- l]cyclopropanecarboxylic acid, 1-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]p- henyl]phenyl]cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]pheny- l]-2-methyl-propanoic acid, 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]p- henyl]phenyl]-2-methyl-propanoic acid, 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphen- ylyl)cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl- }-4-biphenylyl)cyclopropanecarboxylic acid, 1-{3-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]- -4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}- -3-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-{2-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]- -4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl-- 2-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-(2-Chloro-4'-{5-[1-(o-chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyr- azol-1-yl}-4-biphenylyl)cyclopropanecarboxylic acid, 1-(4-{p-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]phenyl}- tolyl)cyclopropanecarboxylic acid, 1-[4-(p-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}phenyl)tolyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyri- dyl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(2-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y- l]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}-2-pyridyl)-2-fluorophenyl]cyclopropanecarboxylic acid, 1-(3-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y- l]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyrid- yl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y- l}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyrid- yl}-2-fluorophenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y- l}-2-pyridyl)-2-fluorophenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyrid- yl}-3-fluorophenyl)cyclopropanecarboxylic acid, and 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y- l}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid. 3. The method according to claim 1, wherein the compound is (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid. 4. The method according to claim 1, wherein the compound is 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphen- ylyl}cyclopropanecarboxylic acid. 5. The method according to claim 1, wherein the lysophosphatidic acid-dependent disease or condition is liver fibrosis. 6. The method according to claim 1, wherein the lysophosphatidic acid-dependent disease or condition is nonalcoholic steatohepatitis (NASH). 7. The method according to claim 6, further comprising: coadministering to the subject a therapeutically active agent selected from the group consisting of pioglitazone, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, nisvastatin, rosuvastatin, and chemokine receptor antagonists. 8. The method according to claim 1, wherein the lysophosphatidic acid-dependent disease or condition is nephropathy. 9. The method according to claim 1, wherein the lysophosphatidic acid-dependent disease or condition is diabetic nephropathy. 10. The method according to claim 9, further comprising: coadministering to the subject a therapeutically active agent selected from the group consisting of losartan, valsartan, candesartan, irbesartan, telmisartan, olmesartan, enalapril, mast cell stabilizers, antihistamines, ketotifen, olopatadine, and rupatadine. 11. A method for treatment of a lysophosphatidic acid-dependent disease or condition in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an active compound and a pharmaceutically acceptable excipient, the active compound having the structure of Formula I ##STR00112## or a pharmaceutically acceptable salt or prodrug thereof, wherein R.sup.A is --CO.sub.2H, --CO.sub.2R.sup.B, --CN, tetrazolyl, --C(.dbd.O)NH.sub.2, --C(.dbd.O)NHR.sup.B, --C(.dbd.O)NHSO.sub.2R.sup.B, or --C(.dbd.O)NHCH.sub.2CH.sub.2SO.sub.3H or a carboxylic acid isostere selected from the group consisting of ##STR00113## wherein R.sup.B is --H or --C.sub.1-C.sub.4 alkyl or has the structure of one of: ##STR00114## L.sup.1 is absent or substituted or unsubstituted C.sub.1-C.sub.6 alkylene, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkylene, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkylene, or substituted or unsubstituted C.sub.1-C.sub.6 heteroalkylene; L.sup.2 is absent; Ring B has the structure of: ##STR00115## and is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where when Ring B is substituted then Ring B is substituted with 1, 2, or 3 independently selected R.sup.H, wherein A.sup.1, A.sup.2, and A.sup.3 are independently N or C; Ring A is a 5 membered heteroarene selected from one of: ##STR00116## wherein the dashed line indicates the point of attachment of Ring A to Ring B, wherein R.sup.C is --CN, --F, --Cl, --Br, --I, --OC.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 fluoroalkyl; and R.sup.D is --N(R.sup.F)--C(.dbd.O)XCH(R.sup.G)--CY, --N(R.sup.F)C(.dbd.O)XC(R.sup.G).sub.2--CY, --N(R.sup.F)C(.dbd.O)X--CY, --C(.dbd.O)N(R.sup.F)CH(R.sup.G)X--CY, or --C(.dbd.O)--N(R.sup.F)C(R.sup.G).sub.2X--CY, wherein X is absent, --O--, --NH-- or --CH.sub.2--; R.sup.E is --H, --C.sub.1-C.sub.4 alkyl or --C.sub.1-C.sub.4 fluoroalkyl; R.sup.F is --H or C.sub.1-C.sub.4 alkyl; R.sup.G is independently selected from R.sup.E, or one R.sup.G is C.sub.1-C.sub.4 alkyl and is taken together with CY and the carbon atom to which R.sup.G and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other R.sup.G, when present, is as defined for R.sup.E; CY is substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein when CY is substituted then CY is substituted with 1, 2, or 3 independently selected R.sup.H; wherein each R.sup.H is independently selected from --H, halogen, --CN, --NO.sub.2, --OH, --OR.sup.J, --SR.sup.J, --S(.dbd.O)R.sup.J, --S(.dbd.O).sub.2R.sup.J, --N(R.sup.J)S(.dbd.O).sub.2R.sup.J, --S(.dbd.O).sub.2N(R.sup.L).sub.2, --C(.dbd.O)R.sup.J, OC(.dbd.O)R.sup.J, --C(.dbd.O)OR.sup.J, --OC(.dbd.O)OR.sup.J, --N(R.sup.L).sub.2, --C(.dbd.O)N(R.sup.L).sub.2, --OC(.dbd.O)N(R.sup.L).sub.2, --N(R.sup.J)C(.dbd.O)N(R.sup.L).sub.2, --N(R.sup.J)C(.dbd.O)R.sup.J, --N(R.sup.J)C(.dbd.O)OR.sup.J, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 fluoroalkyl, C.sub.1-C.sub.4 fluoroalkoxy, C.sub.1-C.sub.4 alkoxy, and C.sub.1-C.sub.4 heteroalkyl, wherein each R.sup.J is independently substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6 heteroalkyl, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkyl, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heterocycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted aryl), or --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heteroaryl); wherein each R.sup.L is independently --H, substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6 heteroalkyl, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkyl, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted cycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heterocycloalkyl), --C.sub.1-C.sub.4 alkylene(substituted or unsubstituted aryl), or --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heteroaryl), or when R.sup.H is --S(.dbd.O).sub.2N(R.sup.L).sub.2, --N(R.sup.L).sub.2, --C(.dbd.O)N(R.sup.L).sub.2, --OC(.dbd.O)N(R.sup.L).sub.2 or N(R.sup.J)C(.dbd.O)N(R.sup.L).sub.2, each R.sup.L is independently --H or C.sub.1-C.sub.6 alkyl, or the R.sup.L groups independently are C.sub.1-C.sub.6 alkyl, which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle; and Ring C is substituted or unsubstituted C.sub.3-C.sub.10 cycloalkylene, substituted or unsubstituted C.sub.2-C.sub.10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where when Ring C is substituted then Ring C is substituted with 1, 2, or 3 independently selected R.sup.H, wherein R.sup.H is as previously defined. 12. The method according to claim 11, wherein the pharmaceutical composition comprises one or two active compounds having the structure of Formula I. 13. The method according to claim 11, wherein the pharmaceutical composition is a solid formulation selected from the group consisting of a tablet, a capsule, a caplet, and a gelcap, and the administering is performed orally. 14. The method according to claim 11, wherein the pharmaceutical composition is a liquid formulation selected from the group consisting of a syrup, a gel, and an ointment, and the administering is performed parenterally or enterally. 15. The method according to claim 11, further comprising: coadministering to the subject a therapeutically active agent selected from the group consisting of corticosteroids, immunosuppressants, analgesics, anti-cancer agents, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, platelet activating factor receptor antagonists, monoacylglycerol kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, mast cell stabilizers, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, .beta.-2 agonists, and combinations thereof. 16. The method according to claim 11, further comprising: coadministering to the subject a therapeutic agent selected from the group consisting of gossypol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib, geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD 184352, paclitaxel, and analogs of Taxol, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; amino glutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; deazaguanine; deazaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II, interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spiro germanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozotocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfm; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, mechloroethamine, cyclophosphamide, chlorambucil, meiphalan, ethylenimine, hexamethlymelamine, thiotepa, busulfan, carmustine, lomusitne, semustine, streptozocin, ortriazenes, dacarbazine, methotrexate, fluorouracil, floxouridine, Cytarabine, mercaptopurine, thioguanine, pentostatin, hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate, estrogens, diethlystilbestrol, ethinyl estradiol, tamoxifen, testosterone propionate, fluoxymesterone, flutamide, leuprolide, cisplatin, carboblatin, mitoxantrone, procarbazine, mitotane, amino glutethimide, Erbulozole, Dolastatin 10, Mivobulin isethionate, Vincristine, NSC-639829, Discodermolide, ABT-751, Altorhyrtin A and Altorhyrtin C, Spongistatins 1-9, Cemadotin hydrochloride, Epothilone A, Epothilone B, Epothilone C, Epothilone D, Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone AN-oxide, 16-aza-epothilone B, 21 aminoepothilone B, 21-hydroxyepothilone D, 26-fluoroepothilone, Auristatin PE, Soblidotin, Cryptophycin 52, Vitilevuamide, Tubulysin A, Canadensol, Centaureidin, Oncocidin Al Fijianolide B, Laulimalide, Narcosine, Nascapine, Hemiasterlin, Vanadocene acetylacetonate, Indanocine Eleutherobins, Caribaeoside, Caribaeolin, Halichondrin B, Diazonamide A, Taccalonolide A, Diozostatin, (-)-Phenylahistin, Myoseverin B, Resverastatin phosphate sodium, Aprepitant, cannabis, marinol, dronabinol, erythropoetin-.alpha., Filgrastim, rituximab, natalizumab, cyclophosphamide, penicillamine, cyclosporine, nitrosoureas, cisplatin, carboplatin, oxaliplatin, methotrexate, azathioprine, mercaptopurine, pyrimidine analogues, protein synthesis inhibitors, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, Atgam.RTM. Thymoglobuline.RTM., OKT3.RTM., basiliximab, daclizumab, cyclosporin, tacrolimus, sirolimus, Interferons, opioids, infliximab, etanercept, adalimumab, golimumab, leflunomide, sulfasalazine, hydroxychloroquinine, minocycline, rapamicin, mycophenolic acid, mycophenolate mofetil, FTY720, Cyclosporin A (CsA) or tacrolimus (FK506), aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, flurobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, valdecoxib, parecoxib, etoricoxib, lumiracoxib, betamethasone, prednisone, alclometasone, aldosterone, amcinonide, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, cortivazol, deflazacort, deoxycorticosterone, desonide, desoximetasone, desoxycortone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluprednidene, fluticasone, formocortal, halcinonide, halometasone, hydrocortisone/cortisol, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone butyrate, loteprednol, medrysone, meprednisone, methylprednisolone, methylprednisolone aceponate, mometasone furoate, paramethasone, prednicarbate, prednisone/prednisolone, rimexolone, tixocortol, triamcinolone, ulobetasol, pioglitazone, clofibrate, fenofibrate gemfibrozil, folic acid, isbogrel, ozagrel, ridogrel, dazoxiben, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, nisvastatin, and rosuvastatin, edaravone, vitamin C, citicoline and minicycline, (2R)-2-propyloctanoic acid, propranolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, esmolol and acebutolol, memantine, traxoprodil, tirofiban lamifiban, argatroban, enalapril, cyclandelate, losartan, valsartan, candesartan, irbesartan, telmisartan, olmesartan mepyramine pyrilamine, antazoline, diphenhydramine, carbinoxamine, doxylamine, clemastine, dimenhydrinate, pheniramine, chlorphenamine chlorpheniramine, dexchlorpheniramine, brompheniramine, triprolidine, cetirizine, cyclizine, chlorcyclizine, hydroxyzine, meclizine, loratadine, desloratidine, promethazine, alimemazine, trimeprazine, cyproheptadine, azatadine, ketotifen, acrivastine, astemizole, cetirizine, mizolastine, terfenadine, azelastine, epinastine, levocabastine, olopatadine, levocetirizine, fexofenadine, rupatadine, bepotastine, mucolytics, anticholinergics, antitussives, analgesics, expectorants, albuterol, ephedrine, epinephrine, fomoterol, metaproterenol, terbutaline, budesonide, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, ipratropium bromide, pseudoephedrine, theophylline, montelukast, pranlukast, tomelukast, zafirlukast, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, treprostinil, pirfenidone, epinephrine, isoproterenol, orciprenaline, xanthines, zileuton, and combinations thereof. 17. The method according to claim 11, wherein the lysophosphatidic acid-dependent disease or condition is fibrosis, liver disease, acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, cell proliferative disease, cancer, inflammatory disease, psoriasis, nephropathy, diabetic nephropathy, pneumonia, gastrointestinal tract disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, renal disease, urinary tract-associated disease, benign prostatic hyperplasia, symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease, inflammatory disease of lower urinary tract, dysuria, frequent urination, pancreas disease, abnormal angiogenesis-associated disease, arterial obstruction, scleroderma, brain-associated disease, cerebral infarction, cerebral hemorrhage, nervous system diseases, neuropathic pain, peripheral neuropathy, pruritus, ocular disease, age-related macular degeneration (AMD), diabetic retinopathy, uveitis, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, or glaucoma filtration surgery scarring. 18. The method according to claim 11, wherein the lysophosphatidic acid-dependent disease or condition is liver fibrosis, nonalcoholic steatohepatitis, nephropathy, or diabetic nephropathy. 19. The method according to claim 11, wherein the active compound comprises at least one of (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, and 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphen- ylyl}cyclopropanecarboxylic acid. 20. A method for reducing signal transduction through a lysophosphatidic acid receptor (LPAR), the method comprising: contacting the LPAR with a compound having the structure of Formula I ##STR00117## or a pharmaceutically acceptable salt or prodrug thereof, wherein R.sup.A is --CO.sub.2H, --CO.sub.2R.sup.B, --CN, tetrazolyl, --C(.dbd.O)NH.sub.2, --C(.dbd.O)NHR.sup.B, --C(.dbd.O)NHSO.sub.2R.sup.B, or --C(.dbd.O)NHCH.sub.2CH.sub.2SO.sub.3H or a carboxylic acid isostere selected from the group consisting of ##STR00118## wherein R.sup.B is --H or --C.sub.1-C.sub.4 alkyl, or has the structure of one of: ##STR00119## L.sup.1 is absent or substituted or unsubstituted C.sub.1-C.sub.6 alkylene, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkylene, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkylene, or substituted or unsubstituted C.sub.1-C.sub.6 heteroalkylene; L.sup.2 is absent; Ring B has the structure of: ##STR00120## and is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where when Ring B is substituted then Ring B is substituted with 1, 2, or 3 independently selected R.sup.H, wherein A.sup.1, A.sup.2, and A.sup.3 are independently N or C; Ring A is a 5 membered heteroarene selected from one of: ##STR00121## wherein the dashed line indicates the point of attachment of Ring A to Ring B, wherein R.sup.C is --CN, --F, --Cl, --Br, --I, --OC.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 fluoroalkyl; and R.sup.D is --N(R.sup.F)--C(.dbd.O)XCH(R.sup.G)--CY, --N(R.sup.F)C(.dbd.O)XC(R.sup.G).sub.2--CY, --N(R.sup.F)C(.dbd.O)X--CY, --C(.dbd.O)N(R.sup.F)CH(R.sup.G)X--CY, or --C(.dbd.O)--N(R.sup.F)C(R.sup.G).sub.2X--CY, wherein X is absent, --O--, --NH-- or --CH.sub.2--; R.sup.E is --H, --C.sub.1-C.sub.4 alkyl or --C.sub.1-C.sub.4 fluoroalkyl; R.sup.F is --H or C.sub.1-C.sub.4 alkyl; R.sup.G is independently selected from R.sup.E, or one R.sup.G is C.sub.1-C.sub.4 alkyl and is taken together with CY and the carbon atom to which R.sup.G and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other R.sup.G, when present, is as defined for R.sup.E; CY is substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein when CY is substituted then CY is substituted with 1, 2, or 3 independently selected R.sup.H; wherein each R.sup.H is independently selected from --H, halogen, --CN, --NO.sub.2, --OH, --OR.sup.J, --SR.sup.J, --S(.dbd.O)R.sup.J, --S(.dbd.O).sub.2R.sup.J, --N(R.sup.J)S(.dbd.O).sub.2R.sup.J, --S(.dbd.O).sub.2N(R.sup.L).sub.2, --C(.dbd.O)R.sup.J, OC(.dbd.O)R.sup.J, --C(.dbd.O)OR.sup.J, --OC(.dbd.O)OR.sup.J, --N(R.sup.L).sub.2, --C(.dbd.O)N(R.sup.L).sub.2, --OC(.dbd.O)N(R.sup.L).sub.2, --N(R.sup.J)C(.dbd.O)N(R.sup.L).sub.2, --N(R.sup.J)C(.dbd.O)R.sup.J, --N(R.sup.J)C(.dbd.O)OR.sup.J, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 fluoroalkyl, C.sub.1-C.sub.4 fluoroalkoxy, C.sub.1-C.sub.4 alkoxy, and C.sub.1-C.sub.4 heteroalkyl, wherein each R.sup.J is independently substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6 heteroalkyl, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkyl, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heterocycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted aryl), or --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heteroaryl); wherein each R.sup.L is independently --H, substituted or unsubstituted C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6 heteroalkyl, substituted or unsubstituted C.sub.1-C.sub.6 fluoroalkyl, substituted or unsubstituted C.sub.3-C.sub.6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted cycloalkyl), --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heterocycloalkyl), --C.sub.1-C.sub.4 alkylene(substituted or unsubstituted aryl), or --C.sub.1-C.sub.4 alkylene-(substituted or unsubstituted heteroaryl), or when R.sup.H is --S(.dbd.O).sub.2N(R.sup.L).sub.2, --N(R.sup.L).sub.2, --C(.dbd.O)N(R.sup.L).sub.2, --OC(.dbd.O)N(R.sup.L).sub.2 or N(R.sup.J)C(.dbd.O)N(R.sup.L).sub.2, each R.sup.L is independently --H or C.sub.1-C.sub.6 alkyl, or the R.sup.L groups independently are C.sub.1-C.sub.6 alkyl, which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle; and Ring C is substituted or unsubstituted C.sub.3-C.sub.10 cycloalkylene, substituted or unsubstituted C.sub.2-C.sub.10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where when Ring C is substituted then Ring C is substituted with 1, 2, or 3 independently selected R.sup.H, wherein R.sup.H is as previously defined. 21. The method according to claim 20, wherein the compound is selected from: 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-- 1-yl]phenyl]phenyl]acetic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-- pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-2-methyl-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1- -yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y- l]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-py- razol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]pheny- l]acetic acid, 1-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]pheny- l]cyclopropanecarboxylic acid, 1-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]p- henyl]phenyl]cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]pheny- l]-2-methyl-propanoic acid, 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]p- henyl]phenyl]-2-methyl-propanoic acid, 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphen- ylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl- }-4-biphenylyl)cyclopropanecarboxylic acid, 1-{3-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]- -4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl- }-3-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-{2-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]- -4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl- }-2-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-(2-Chloro-4'-{5-[1-(o-chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyr- azol-1-yl}-4-biphenylyl)cyclopropanecarboxylic acid, 1-(4-{p-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]phenyl}- tolyl)cyclopropanecarboxylic acid, 1-[4-(p-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}phenyl)tolyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyri- dyl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(2-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y- l]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}-2-pyridyl)-2-fluorophenyl]cyclopropanecarboxylic acid, 1-(3-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y- l]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-- yl}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyrid- yl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y- l}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyrid- yl}-2-fluorophenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y- l}-2-pyridyl)-2-fluorophenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyrid- yl}-3-fluorophenyl)cyclopropanecarboxylic acid, and 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y- l}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid. 22. The method according to claim 20, wherein the LPAR is in a subject having a lysophosphatidic acid-dependent disease. 23. The method according to claim 16, wherein the analogs of Taxol are selected from the group consisting of Taxotere, U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600 125, BAY 43-9006, wortmannin, LY294002, and combinations thereof. 24. The method according to claim 16, wherein the Eleutherobins are selected from the group consisting of Desmethyleleutherobin, Desacetyleleutherobin, Isoeleutherobin A, Z-Eleutherobin, and combinations thereof.

Details for Patent 10,570,103

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2033-03-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2033-03-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2033-03-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2033-03-15
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	06/04/1986		2033-03-15